Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Profit After Tax (2023 - 2025)

Immunome's Profit After Tax history spans 3 years, with the latest figure at -$69.9 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 12.9% year-over-year to -$69.9 million; the TTM value through Dec 2025 reached -$212.4 million, up 27.5%, while the annual FY2025 figure was -$212.4 million, 27.5% up from the prior year.
  • Profit After Tax reached -$69.9 million in Q4 2025 per IMNM's latest filing, down from -$57.5 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$4.3 million in Q1 2023 to a low of -$129.5 million in Q1 2024.
  • Average Profit After Tax over 3 years is -$51.0 million, with a median of -$45.2 million recorded in 2024.
  • Peak YoY movement for Profit After Tax: crashed 2932.6% in 2024, then surged 67.84% in 2025.
  • A 3-year view of Profit After Tax shows it stood at -$92.6 million in 2023, then increased by 13.37% to -$80.2 million in 2024, then increased by 12.9% to -$69.9 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Profit After Tax are -$69.9 million (Q4 2025), -$57.5 million (Q3 2025), and -$43.4 million (Q2 2025).